Literature DB >> 18476098

Impact of anaerobic growth conditions on toxic shock syndrome toxin-i production by Staphylococcus aureus.

M Lungren1, P Chaisilwattana, F C Knoop, G R Monif.   

Abstract

OBJECTIVE: The impact of anaerobic growth conditions on the Staphylococcus aureus toxic shock syndrome toxin-1 (TSST-1) production was studied.
METHODS: Ten strains of S. aureus derived from patients with toxic shock syndrome (TSS), 10 isolates of S. aureus, and documented TSST-1-producing strains recovered from patients with either staphylococcal septicemia or staphylococcal nongenital abscesses were grown under aerobic and anaerobic conditions. The bacterial growth was measured using optical density (OD) determinations at 520 nm. The toxin production was assayed using the TS-RPLA latex agglutination test.
RESULTS: Both TSS and non-TSS strains of S. aureus grown under aerobic and anaerobic conditions exhibited comparable OD patterns of growth, and the levels of toxin production remained constant during the logarithmic phase. Toxin titers developed during the logarithmic growth phase and peaked after 24 h of incubation. When stationary-phase isolates grown initially under aerobic conditions were subjected to strict anaerobic conditions, subsequent toxin titers, compared with isolates grown in the continued presence of oxygen, were depressed 2-fold, peaking at a later time.
CONCLUSIONS: TSST-1 production is diminished under continued anaerobic conditions.

Entities:  

Year:  1996        PMID: 18476098      PMCID: PMC2364497          DOI: 10.1155/S1064744996000440

Source DB:  PubMed          Journal:  Infect Dis Obstet Gynecol        ISSN: 1064-7449


  11 in total

1.  Production, purification, and chemical characterization of Staphylococcus aureus exfoliative toxin.

Authors:  A D Johnson; J F Metzger; L Spero
Journal:  Infect Immun       Date:  1975-11       Impact factor: 3.441

2.  Toxin and enzyme characterization of Staphylococcus aureus isolates from patients with and without toxic shock syndrome.

Authors:  P M Schlievert; M T Osterholm; J A Kelly; R D Nishimura
Journal:  Ann Intern Med       Date:  1982-06       Impact factor: 25.391

3.  A new staphylococcal enterotoxin, enterotoxin F, associated with toxic-shock-syndrome Staphylococcus aureus isolates.

Authors:  M S Bergdoll; B A Crass; R F Reiser; R N Robbins; J P Davis
Journal:  Lancet       Date:  1981-05-09       Impact factor: 79.321

4.  Identification and characterization of an exotoxin from Staphylococcus aureus associated with toxic-shock syndrome.

Authors:  P M Schlievert; K N Shands; B B Dan; G P Schmid; R D Nishimura
Journal:  J Infect Dis       Date:  1981-04       Impact factor: 5.226

5.  Production of staphylococcal pyrogenic exotoxin type C: influence of physical and chemical factors.

Authors:  P M Schlievert; D A Blomster
Journal:  J Infect Dis       Date:  1983-02       Impact factor: 5.226

6.  Toxic shock syndrome in the postoperative patient.

Authors:  K J Dornan; D M Thompson; A R Conn; B K Wittmann; H G Stiver; A W Chow
Journal:  Surg Gynecol Obstet       Date:  1982-01

7.  Cryptogenic acute cholangitis--association with toxic shock syndrome.

Authors:  K G Ishak; W A Rogers
Journal:  Am J Clin Pathol       Date:  1981-11       Impact factor: 2.493

8.  Toxic-shock syndrome in menstruating women: association with tampon use and Staphylococcus aureus and clinical features in 52 cases.

Authors:  K N Shands; G P Schmid; B B Dan; D Blum; R J Guidotti; N T Hargrett; R L Anderson; D L Hill; C V Broome; J D Band; D W Fraser
Journal:  N Engl J Med       Date:  1980-12-18       Impact factor: 91.245

9.  Toxic-shock syndrome: epidemiologic features, recurrence, risk factors, and prevention.

Authors:  J P Davis; P J Chesney; P J Wand; M LaVenture
Journal:  N Engl J Med       Date:  1980-12-18       Impact factor: 91.245

10.  Alteration of immune function by staphylococcal pyrogenic exotoxin type C: possible role in toxic-shock syndrome.

Authors:  P M Schlievert
Journal:  J Infect Dis       Date:  1983-03       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.